ArticleJournal of virology2014
Human papillomavirus 45 genetic variation and cervical cancer risk worldwide.
Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Lineages and sublineages of high-risk human papillomavirus types associated with cervical cancer and precancer: a systematic review and meta-analysis.Journal of the National Cancer Institute · 2025Pooled it
- Diverse non-vaccine high-risk HPV genotypes in rural Kerala: implications for cervical cancer prevention in an underserved population.Infectious agents and cancer · 2026Article
- Evolutionary Dynamics of Human Papillomavirus in Thailand: Immunoinformatic Design of a Synergistic L1/L2 Vaccine Candidate.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A multi-centre study on cervical cancer screening reveals population-related impact on cervical intraepithelial neoplasia rate.Frontiers in cellular and infection microbiology · 2026Article
- Vaccine-preventable HPV burden and cervical abnormalities in women during 2022-2024 Octobre Rose campaigns in Libreville.Nature communications · 2025Article
- High prevalence and atypical genotype distribution of oral human Papillomavirus in an East African HIV cohort: a cross-sectional study.BMC infectious diseases · 2025Article
- Human Papillomavirus Infection as a Rare Etiological Factor in Moderate Squamous Dysplasia of the Trachea.Diagnostics (Basel, Switzerland) · 2025Article
- Whole-genome sequencing of 1,083 HPV45 cases and controls identifies genetic variants associated with glandular cervical lesions.International journal of cancer · 2025Article
- Article
- PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Surgical Advancements, Immunotherapy, Targeted and Conventional Therapies, Biopsy, Colposcopy, and Pap Smear Integration in the Management of Cervical Cancer.Current medicinal chemistry · 2025Review
- Analysis of Human Papillomavirus-HPV-18 and HPV-45 Type-specific variants in a contemporary cohort of individuals with cervical disease in Ghana.Ghana medical journal · 2024Article
- Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection.Nature communications · 2024Article
- In silico analysis of HLA-1 and HLA-2 recognition of a designed recombinant human papillomavirus vaccine based on L1 protein HPV subtype 45.Journal, genetic engineering & biotechnology · 2023Article
- Genomic Risk Factors for Cervical Cancer.Cancers · 2021Review
- Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.Journal of virology · 2020Article
- Phylogeny and In Silico Structure Analysis of Major Capsid Protein (L1) Human Papillomavirus 45 from Indonesian Isolates.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation.Frontiers in public health · 2020Review
- Self-Collected Specimens Revealed a Higher Vaccine- and Non-Vaccine-Type Human Papillomavirus Prevalences in a Cross-Sectional Study in Akuse.Advances in preventive medicine · 2020Article
- Mucosal and Cutaneous Human Papillomavirus Infections and Cancer Biology.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
unlabelledHuman papillomavirus 45 (HPV45) is a member of the HPV18-related alpha-7 species and accounts for approximately 5% of all cervical cancer cases worldwide. This study evaluated the genetic diversity of HPV45 and the association of HPV45 variants with the risk of cervical cancer by sequencing the entire E6 and E7 open reading frames of 300 HPV45-positive cervical samples from 36 countries. A total of 43 HPV45 sequence variants were identified that formed 5 phylogenetic sublineages, A1, A2, A3, B1, and B2, the distribution of which varied by geographical region. Among 192 cases of cervical cancer and 101 controls, the B2 sublineage was significantly overrepresented in cervical cancer, both overall and in Africa and Europe separately. We show that the sequence analysis of E6 and E7 allows the classification of HPV45 variants and that the risk of cervical cancer may differ by HPV45 variant sublineage. IMPORTANCE: This work describes the largest study to date of human papillomavirus 45 (HPV45)-positive cervical samples and provides a comprehensive reference for phylogenetic classification for use in epidemiological studies of the carcinogenicity of HPV45 genetic variants, particularly as our findings suggest that the B2 sublineage of HPV45 is associated with a higher risk of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.